Summit Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview

Summit Therapeutics

14/02/2025 13:39

* Summit Therapeutics Inc  SMMT.OQ   SMMT.O  is expected
to report
resultson February 18 (estimated) for the period ending December
31 2024
    * 
    * ​LSEG's mean analyst estimate for Summit Therapeutics Inc
is for
a loss of 8 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Summit
Therapeutics Inc is $32.00​, above​ its last closing price
of $21.82. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.06       -0.07      -0.08     Missed  -20
 Jun. 30 2024  -0.06       -0.06      -0.09     Missed  -45.2
 Mar. 31 2024  -0.06       -0.06      -0.06     Met     0​
 ​​                                                     
                                                        ​
 This summary was machine generated February 14 at 13:39 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)